LMR Partners’s Intra-Cellular Therapies Inc. ITCI Stock Holding History

LMR Partners’s Portfolio ITCI Stock Details ITCI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q2	–	Sell	-991,100	Closed	-$131M	–	1738
2025 Q1	$131M	Buy	+991,100	New	+$124M	1.22%	5
2024 Q3	–	Sell	-7,600	Closed	-$521K	–	1588
2024 Q2	$521K	Sell	7,600 -221,000	-97%	-$15.3M	﹤0.01%	765
2024 Q1	$15.8M	Buy	228,600 +104,800	+85%	+$7.2M	0.16%	133
2023 Q4	$8.87M	Buy	123,800 +92,600	+297%	+$5.33M	0.1%	215
2023 Q3	$1.63M	Sell	31,200 -13,300	-30%	-$775K	0.02%	423
2023 Q2	$2.82M	Buy	+44,500	New	+$2.77M	0.03%	309

Other funds holding ITCI

DekaBank Deutsche Girozentrale Frankfurt, Germany $60.6B AUM 23.27% 1-Year Est. Return

Osaic Holdings Scottsdale, Arizona $68.3B AUM 20.5% 1-Year Est. Return

KIM

Kestra Investment Management Austin, Texas $5.8B AUM 14.71% 1-Year Est. Return

HNB

Huntington National Bank Columbus, Ohio $18.1B AUM 24.69% 1-Year Est. Return

LMR Partners's ITCI Position: Q2 2025 in Review

LMR Partners sold out of Intra-Cellular Therapies Inc. (ITCI) in Q2 2025, closing a stake of 863,134 shares — an estimated $114M sold.

LMR Partners first reported a position in ITCI in Q4 2019 and held it in 12 quarters. The position peaked at $114M in Q1 2025. 4 funds tracked by Wall St. Rank hold ITCI as of Q2 2025.

LMR Partners reported no remaining Intra-Cellular Therapies Inc. position as of Q2 2025 after selling out during the quarter.
LMR Partners sold 863,134 Intra-Cellular Therapies Inc. shares in Q2 2025, an estimated $114M.
LMR Partners first reported a position in Intra-Cellular Therapies Inc. in Q4 2019 and held it in 12 quarters.
LMR Partners's Intra-Cellular Therapies Inc. position peaked at $114M in Q1 2025.
4 funds tracked by Wall St. Rank held Intra-Cellular Therapies Inc. as of Q2 2025.

Based on LMR Partners's 13F filing for Q2 2025, filed 14 Aug 2025.